Technical Analysis for HARP - Harpoon Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
A | 23.01 | 0.09% | 0.02 |
HARP closed up 0.09 percent on Friday, March 8, 2024, on 4.63 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Mar 25
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | Up | Up | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 118.10% | |
Wide Bands | Range Expansion | 118.10% | |
Gapped Up | Strength | 118.10% | |
20 DMA Support | Bullish | 114.85% | |
Wide Bands | Range Expansion | 114.85% | |
20 DMA Support | Bullish | 118.52% | |
Wide Bands | Range Expansion | 118.52% | |
Down 3 Days in a Row | Weakness | 118.52% | |
Down 4 Days in a Row | Weakness | 118.52% | |
Down 5 Days in a Row | Weakness | 118.52% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/25/2024
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Disease Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Prostate Cancer Ovarian Cancer Small Cell Lung Cancer Multiple Myeloma Proteins Treatment Of Ovarian Cancer Resistant Prostate Cancer Metastatic Castration Resistant Prostate Cancer Mesothelin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Disease Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Prostate Cancer Ovarian Cancer Small Cell Lung Cancer Multiple Myeloma Proteins Treatment Of Ovarian Cancer Resistant Prostate Cancer Metastatic Castration Resistant Prostate Cancer Mesothelin
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 23.21 |
52 Week Low | 3.11 |
Average Volume | 1,430,201 |
200-Day Moving Average | 10.84 |
50-Day Moving Average | 20.95 |
20-Day Moving Average | 22.76 |
10-Day Moving Average | 22.96 |
Average True Range | 0.19 |
RSI (14) | 82.67 |
ADX | 69.3 |
+DI | 47.00 |
-DI | 6.50 |
Chandelier Exit (Long, 3 ATRs) | 22.63 |
Chandelier Exit (Short, 3 ATRs) | 22.90 |
Upper Bollinger Bands | 23.25 |
Lower Bollinger Band | 22.28 |
Percent B (%b) | 0.75 |
BandWidth | 4.26 |
MACD Line | 0.58 |
MACD Signal Line | 0.75 |
MACD Histogram | -0.1692 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 23.06 | ||||
Resistance 3 (R3) | 23.05 | 23.04 | 23.05 | ||
Resistance 2 (R2) | 23.04 | 23.03 | 23.04 | 23.04 | |
Resistance 1 (R1) | 23.02 | 23.02 | 23.03 | 23.03 | 23.04 |
Pivot Point | 23.01 | 23.01 | 23.01 | 23.01 | 23.01 |
Support 1 (S1) | 22.99 | 23.00 | 23.00 | 23.00 | 22.98 |
Support 2 (S2) | 22.98 | 22.99 | 22.98 | 22.98 | |
Support 3 (S3) | 22.96 | 22.98 | 22.97 | ||
Support 4 (S4) | 22.97 |